Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L‐asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK /T‐cell lymphoma: A French retrospective study

Archive ouverte

Chaubard, Sammara | Marouf, Amira | Lavergne, David | Lemonnier, François | Rossignol, Julien | Clavert, Aline | Gressin, Rémy | Cartron, Guillaume | Waultier-Rascalou, Agathe | Vargaftig, Jacques | Salles, Gilles | Bachy, Emmanuel | Ghesquières, Hervé | Tournilhac, Olivier | Chauchet, Adrien | Le Gouill, Steven | Damaj, Gandhi | Fornecker, Luc-Matthieu | Sibon, David | Obéric, Lucie | Michot, Jean-Marie | Gaulard, Philippe | Hermine, Olivier | Couronné, Lucile | Jaccard, Arnaud

Edité par CCSD ; Wiley -

International audience. Extranodal NK/T‐cell lymphoma, nasal type is a rare and aggressive form of lymphoma, historically associated with poor prognosis. We report here the results of a retrospective multi‐centre study evaluating the efficacy of MGAD (methotrexate, gemcitabine, L‐asparaginase and dexamethasone) regimen (two cycles) combined with ‘sandwich’ radiotherapy in 35 patients with localised newly diagnosed extranodal NK/T‐cell lymphoma. Thirty‐two patients (91%) reached complete remission. With a long median follow‐up of 59.6 months, progression‐free and overall survival at 2 and 5 years were 71%, 80% and 53%, 73%, respectively. Around one third of the patients experienced relapse within a median time of 14.5 months. Side‐effects were manageable with grades 3–4 cytopenias, mucositis and infection in 50%, 24% and 21% of the cases, respectively. Monitoring of asparaginase activity was performed in 13 patients and showed inactivation of the drug in seven (54%) patients. Our results indicate that a short therapy by sandwich MGAD chemoradiotherapy is a tolerable and effective treatment option in localised newly diagnosed extranodal NK/T‐cell lymphoma patients.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion